[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Fortress Biotech Inc (FBIO)

Fortress Biotech Inc (FBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 79,393
  • Shares Outstanding, K 33,219
  • Annual Sales, $ 63,260 K
  • Annual Income, $ 6,820 K
  • EBIT $ -66 M
  • EBITDA $ -58 M
  • 60-Month Beta 1.16
  • Price/Sales 1.26
  • Price/Cash Flow N/A
  • Price/Book 1.20

Options Overview Details

View History
  • Implied Volatility 343.20% (+19.80%)
  • Historical Volatility 59.56%
  • IV Percentile 92%
  • IV Rank 29.65%
  • IV High 1,000.47% on 11/10/25
  • IV Low 66.25% on 11/20/25
  • Expected Move (DTE 5) 0.37 (15.65%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 6
  • Volume Avg (30-Day) 161
  • Put/Call OI Ratio 0.58
  • Today's Open Interest 7,557
  • Open Int (30-Day) 10,810
  • Expected Range 2.02 to 2.76

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-0.48
  • Growth Rate Est. (year over year) +208,225.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.20 +8.64%
on 04/29/26
2.57 -7.00%
on 05/06/26
+0.08 (+3.46%)
since 04/08/26
3-Month
2.20 +8.64%
on 04/29/26
4.22 -43.36%
on 02/23/26
-0.88 (-26.91%)
since 02/06/26
52-Week
1.60 +49.38%
on 05/13/25
4.53 -47.24%
on 01/09/26
+0.70 (+41.42%)
since 05/08/25

Most Recent Stories

More News
Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026

SCOTTSDALE, Ariz., May 06, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused...

FBIO : 2.39 (-0.42%)
DERM : 5.07 (+1.40%)
Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term...

FBIO : 2.39 (-0.42%)
FBIOP : 13.50 (+0.08%)
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

SCOTTSDALE, Ariz., April 21, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical...

FBIO : 2.39 (-0.42%)
DERM : 5.07 (+1.40%)
Fortress Biotech: Q4 Earnings Snapshot

Fortress Biotech: Q4 Earnings Snapshot

FBIO : 2.39 (-0.42%)
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

ZYCUBO ® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205...

FBIO : 2.39 (-0.42%)
FBIOP : 13.50 (+0.08%)
Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

MIAMI, March 30, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced the closing...

FBIO : 2.39 (-0.42%)
FBIOP : 13.50 (+0.08%)
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi ™  generated net revenues of $14.7 million during the full-year period after its launch in early April 2025...

FBIO : 2.39 (-0.42%)
DERM : 5.07 (+1.40%)
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

SCOTTSDALE, Ariz., March 18, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused...

FBIO : 2.39 (-0.42%)
DERM : 5.07 (+1.40%)
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cyprium...

FBIO : 2.39 (-0.42%)
FBIOP : 13.50 (+0.08%)
Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cyprium...

FBIO : 2.39 (-0.42%)
FBIOP : 13.50 (+0.08%)

Business Summary

Fortress Biotech, Inc. is a biopharmaceutical company. The company is engaged in acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress Biotech, Inc., formerly known as Coronado Biosciences, Inc., is based in NEW YORK, United States.

See More

Key Turning Points

3rd Resistance Point 2.51
2nd Resistance Point 2.48
1st Resistance Point 2.43
Last Price 2.39
1st Support Level 2.35
2nd Support Level 2.32
3rd Support Level 2.27

See More

52-Week High 4.53
Fibonacci 61.8% 3.41
Fibonacci 50% 3.07
Fibonacci 38.2% 2.72
Last Price 2.39
52-Week Low 1.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.